A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration by unknown
REVIEW ARTICLE
A Comprehensive Review of Treprostinil Pharmacokinetics
via Four Routes of Administration
Parag Kumar1,2 • Emily Thudium1 • Kevin Laliberte1 • David Zaccardelli1 •
Andrew Nelsen1
Published online: 10 June 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Treprostinil is available in three different formula-
tions and four different routes of administration: Remodulin
(treprostinil sodium, intravenous and subcutaneous adminis-
tration), Tyvaso (treprostinil sodium, inhaled administration),
and Orenitram (treprostinil diolamine, oral administration)
for the treatment of pulmonary arterial hypertension (PAH).
Pharmacokinetic studies have been performed in healthy vol-
unteers and patients with PAH. The intent of this review is to
outline pharmacokinetic considerations of the three treprostinil
formulations and provide clinicians with a resource that may
support clinical decisions in treating patients with PAH.
Key Points
There are currently three formulations of treprostinil
available for treatment of pulmonary arterial
hypertension (PAH) in four routes of administration:
intravenous (IV), subcutaneous (SC), inhaled, and oral
treprostinil. Each route of administration is associated
with unique pharmacokinetics, dosing considerations,
and potential for route-specific adverse effects.
Parenteral routes of administration (IV, SC) are
bioequivalent at steady state, while inhaled treprostinil
achieves lower systemic concentrations with localized
delivery to the lungs. Oral treprostinil achieves similar
systemic exposure to parenteral administration with a
bioavailability of approximately 17 %.
1 Introduction
Pulmonary arterial hypertension (PAH) is a progressive
and fatal disease, characterized by increasing pulmonary
vascular resistance (PVR), which may eventually lead to
right ventricular failure and premature death [1]. The dis-
ease is defined by a mean pulmonary artery pressure
[25 mmHg at rest, pulmonary arterial wedge pres-
sure B15 mmHg, and PVR[3 Wood units. The cause of
PAH is multi-factorial but may develop due to imbalances
in the endothelin-1, nitric oxide, and prostacyclin path-
ways. These irregularities lead to increased production of
vasoconstricting compounds (e.g., endothelin, thrombox-
ane) and decreased production of vasodilators (e.g.,
prostacyclin), ultimately resulting in pulmonary artery
vasoconstriction and endothelial cell proliferation. Cur-
rently, four classes of compounds are approved for the
treatment of PAH: endothelin receptor antagonists (ERAs),
phosphodiesterase type 5 (PDE-5) inhibitors, soluble
guanylate cyclase stimulators, and prostacyclins.
Treprostinil is a chemically stable, tricyclic analog of
prostacyclin, with a molecular weight of 390.52 (C23H34-
NaO5). The primary mechanism of action of treprostinil is
reduction in pulmonary artery pressure through direct
vasodilation of the pulmonary and systemic arterial vas-
cular beds, thereby improving systemic oxygen transport
and increasing cardiac output with minimal alteration of
the heart rate. Treprostinil has been shown to have high
in vitro affinity for the DP1, EP2, and IP receptors (inhi-
bition constant [Ki] 4.4, 3.6, and 32 nmol/L, respectively)
[2], all of which can result in dilatation of human pul-
monary vasculature upon activation. For the IP receptor
specifically, when endogenous prostacyclin binds, cyclic
adenosine monophosphate is activated. This activation
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accounts for additional mechanisms of prostacyclin action,
including inhibition of pulmonary artery smooth muscle
cell proliferation, inhibition of platelet aggregation, and
reversal of pulmonary artery remodeling [2, 3]. It has also
recently been discovered that in vitro the majority of the
anti-proliferating properties of treprostinil are mediated
through the EP2 receptor [4].
Treprostinil is available in three separate formulations: a
continuous subcutaneous (SC) and intravenous (IV) infu-
sion (Remodulin), a solution for inhalation (Tyvaso),
and an extended-release oral tablet (Orenitram). Par-
enteral and inhaled treprostinil are formulated as the
sodium salt, whereas oral treprostinil is formulated as the
diolamine salt. Clinical effectiveness of these products was
demonstrated by improvement in exercise capacity, as
measured by change in 6-min walk distance (6MWD)
[5–7]. Additionally, a placebo-controlled study examining
the transition of IV epoprostenol to SC treprostinil
demonstrated a delay in time to clinical worsening with
treprostinil [8]. While each treprostinil formulation pro-
vides benefit to patients with PAH, different routes of
administration have the potential to produce distinct
adverse events. For example, 85 % of patients receiving
SC treprostinil in the pivotal trial experienced infusion-site
pain, while 54 and 25 % of patients experienced cough and
throat irritation with inhaled treprostinil [9, 10]. With oral
treprostinil, 6 % of patients experienced abdominal dis-
comfort compared with a placebo rate of 0 % [11]. Table 1
summarizes some of the risks and benefits of each for-
mulation. Understanding the relative pharmacokinetic dif-
ferences of the available treprostinil formulations may
facilitate and support clinical decision making in treating
patients with PAH, especially when transitioning between
treprostinil formulations. The objective of this review is to
provide a summary and comparison of pharmacokinetic
data from studies of treprostinil formulations performed in
Table 1 Risks and benefits of the various treprostinil formulations
Treprostinil routea Risks [9–11] Benefits Other considerations
Placebo-corrected Hodges-
Lehmann median change in
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bid or tid dosing
Take with food
Ability to titrate dose
6MWD 6-min walk distance, bid twice daily, IV intravenous, qid four times daily, SC subcutaneous, tid three times daily
a See Table 2 for additional details on the pivotal trials for each formulation
b Study ongoing. Patients had an opportunity to reach 2 and 3 years of Orenitram therapy
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healthy volunteers and patients with PAH. Details of study
designs and participant populations are provided in
Table 2.
2 Overview of Treprostinil Formulations and Key
Pharmacokinetic Data
2.1 Remodulin (Parenteral Treprostinil Sodium)
Dosing Overview
The preferred route of administering parenteral treprostinil
is SC, but it can be administered by a central IV line if the
SC route is not tolerated due to severe site pain or reaction
[9]. The infusion rate is initiated at 1.25 ng/kg/min. If this
initial dose cannot be tolerated because of systemic effects,
the infusion rate should be reduced to 0.625 ng/kg/min.
The infusion rate should be increased in increments of
1.25 ng/kg/min per week for the first 4 weeks of treatment.
The dose should be further titrated in increments of 2.5 ng/
kg/min per week, as determined by the patient’s clinical
response. If tolerated, dosage adjustments may occur more
frequently.
Currently, the method of parenteral treprostinil delivery
involves an external delivery device. One study is ongoing
in which the objective is to analyze whether an
implantable intravascular delivery system for continuous
drug administration is feasible. A multicenter, prospective,
single-arm, non-randomized study at ten sites involving 60
implanted subjects demonstrated that use of the
implantable intravascular delivery system to administer
parenteral treprostinil significantly reduced the number of
catheter-related complications from a pre-defined criterion
of 2.5 complications per 1000 days with external delivery
devices to 0.27 complications per 1000 days with the
implantable delivery device (p\ 0.0001) [12]. For this
analysis, the mean duration of use was 367 days. The mean
plasma treprostinil concentration was 10.5 ng/mL 1 week
after implantation compared with a baseline level of
10.9 ng/mL, collected when the drug was being adminis-
tered with the external pump [13].
2.1.1 Bioequivalence at Steady State
In a comparative pharmacokinetic crossover study, subjects
received treprostinil (IV or SC) at a dose of 10 ng/kg/min
for 72 h; infusions were separated by a 4-day washout
period [14]. Steady-state ratios of the geometric means (IV/
SC) [90 % confidence intervals (CIs)] for the area under
the plasma concentration–time curve (AUC) and maximal
plasma concentration (Cmax) were 92.9 % [89.8–96.1] and
106 % [99.4–113], respectively (Fig. 1) [14]. When
considering treatment options, these findings indicate that
IV and SC treprostinil are bioequivalent at steady state.
2.1.2 Long-Term Pharmacokinetic and Diurnal Variation
The steady-state pharmacokinetic and potential for diurnal
variation was investigated when administered as a long-
term 28-day continuous SC infusion to healthy adult vol-
unteers [15]. The doses administered were 2.5, 5, 10, and
15 ng/kg/min, and escalations occurred every 7 days with
no washout periods between escalations. Linear regression
analysis of the mean steady-state treprostinil concentration
versus the targeted dose yielded a fitted line with an R2 of
0.92, demonstrating linear and dose-independent pharma-
cokinetics. Consistent diurnal variation cycles of two peaks
and two troughs were observed over a 24-h steady-state
interval for all doses, with peak concentrations approxi-
mately 20–30 % higher than trough levels. Inter-subject
percentage coefficients of variation (CV%) ranged from 14
to 26 % for mean peak and trough concentrations,
respectively.
2.1.3 Dose Linearity in Pulmonary Arterial Hypertension
(PAH) Patients
Dose proportionality was assessed in patients receiving
treprostinil by continuous IV or SC infusion at doses
between 12.1 and 125 ng/kg/min [16]. Steady-state tre-
prostinil plasma concentrations ranged from 14.9 to
18248 pg/mL. A positive correlation between the trepros-
tinil dose and treprostinil plasma concentration following
linear regression analysis was reported, with an R2 value of
0.796. The equation describing the relationship between
the treprostinil dose and steady-state plasma concentration
(pg/mL) was as follows:
Treprostinil concentration
¼ 295:3 þ 140:07 treprostinil doseð Þ:
This study illustrated treprostinil dose–concentration
linearity up to 125 ng/kg/min.
2.2 Tyvaso (Inhaled Treprostinil Sodium) Dosing
Overview
Treprostinil solution for inhalation is administered via an
ultrasonic nebulizer, with the device delivering approxi-
mately 6 lg of treprostinil per breath [10]. The initial dose
of Tyvaso is 3 breaths (18 lg) four times daily, with up-
titration to target maintenance dosage of 9 breaths (54 lg)
four times daily as tolerated. Forty-two percent of patients
in the open-label extension trial achieved a dose of at least
12 breaths (72 lg) four times daily, with qualitatively
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SC PAH patients 470 12-week, double-blind, placebo-controlled, multicenter trial in recently
diagnosed patients receiving no prior background therapy (e.g., endothelin
receptor antagonists, epoprostenol) (mean dose 9.3 ng/kg/min)
2.1.1 IV/SC Healthy volunteers 51 Randomized, open-label, 2-period crossover bioequivalence PK
2.1.2 SC Healthy volunteers 14 Single-center, open-label, non-randomized, long-term, dose-escalation PK




Inhaled PAH patients 235 12-week, randomized, double-blind, placebo-controlled multicenter trial in
clinically stable patients, mostly NYHA class III, receiving background
therapy with either bosentan (70 %) or sildenafil (30 %) for at least
3 months prior to study initiation (mean dose 50 lg qid)
2.2.1 Healthy volunteers 18 Open-label, randomized, three-period crossover, absolute bioavailability
2.2.2 Healthy volunteers 40 Double-blind, randomized, placebo-controlled, single-dose, dose-escalation,
maximum tolerated dose PK




Oral PAH patients 349 12-week, double-blind, placebo-controlled, multicenter trial in recently
diagnosed patients receiving no prior background therapy (e.g., endothelin
receptor antagonists, phosphodiesterase type 5 inhibitor) (mean dose
3.4 mg bid)
2.3.1 Healthy volunteers 10 Open-label, 3-cohort, randomized, 2-period, crossover safety and PK
2.3.1 Healthy volunteers 32 Open-label, randomized, single-dose, 4-period, crossover safety and PK
2.3.1 Healthy volunteers 36 Randomized, double-blind, placebo-controlled, parallel-group, dose-
escalating safety and PK
2.3.2 Healthy volunteers 26 Single-center, randomized, 2-period, crossover, drug interaction study:
acetaminophen
Healthy volunteers 15 Single-center, single-blind, vehicle-controlled, 2-period crossover drug
interaction study: warfarin
Healthy volunteers 22 Single-center, open-label, 3-period, 3-sequence crossover, drug interaction
study: Tracleer
Healthy volunteers 17 Single-center, open-label, 3-period, 3-sequence crossover, drug interaction
study: Revatio
Healthy volunteers 20 Single-center, open-label, single-sequence, drug interaction study: rifampin
Healthy volunteers 40 Single-center, open-label, single-sequence, drug interaction study:
fluconazole
Healthy volunteers 40 Single-center, open-label, 2-cohort, 2-sequence, 2-period, crossover, drug
interaction study: gemfibrozil
Healthy volunteers 30 Open-label, single-sequence, crossover, drug interaction study: esomeprazole
2.3.3 Hepatic dysfunction and
healthy volunteers
30 Open-label, 3-cohort, safety and PK in patients with varying degrees of
hepatic dysfunction compared with healthy volunteers
2.3.3 Renal dysfunction and
healthy volunteers
16 Open-label safety and PK study pre- and post-dialysis compared with healthy
volunteers
2.3.4 PAH patients 70 Multi-center, open-label, long-term PK substudy
2.3.5 Healthy volunteers 19 9-Day, open-label, single-center, single-group, repeat tid dosing study
PAH patients 13 Single-center, pharmacokinetic and tolerability study comparing bid with tid
dosing
2.3.6 PAH patients 33 Multi-center, open-label, 24-week, safety and tolerability study of subjects
transitioning from continuous IV/SC Remodulin infusion to oral
treprostinil
bid twice daily, IV intravenous, NYHA New York Heart Association, PAH pulmonary arterial hypertension, PK pharmacokinetic, qid four times
daily, SC subcutaneous, tid three times daily
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similar adverse events to the short-term placebo-controlled
trial [10].
2.2.1 Absolute Bioavailability and Dose Linearity
A crossover study to determine the absolute bioavailability
of inhaled treprostinil relative to IV treprostinil was per-
formed in 18 volunteers who were randomized to receive
18 lg of inhaled treprostinil, 36 lg of inhaled treprostinil,
or 15 ng/kg/min (60 min) of IV treprostinil [17]. Both Cmax
and AUC increased proportionally following a single
administration of 18 or 36 lg of inhaled treprostinil, with
mean Cmax and AUC ± standard deviation (%CV)
increasing from 0.354 ± 0.137 (38.8 %) to 0.698 ± 0.141
(20.2 %) ng/mL and from 0.2556 ± 0.0843 (33 %) to
0.6115 ± 0.1751 (28.6 %) ngh/mL, respectively. Mean
estimates of the absolute systemic bioavailability of tre-
prostinil after inhalation were 64.4 % (18 lg, 3 breaths) to
71.6 % (36 lg, 6 breaths) relative to IV treprostinil con-
centrations. Treprostinil concentrations remained
detectable in the plasma approximately 4 h after inhalation.
2.2.2 Maximum Tolerated Dose
The maximum tolerated dose (MTD) and dose linearity of
inhaled treprostinil were evaluated in a study of volunteers
randomized to receive 54, 72, 78, 84, or 90 lg of inhaled
treprostinil [17]. Mean systemic exposures (AUC from
time zero to infinity [AUC?]) (%CV) after inhaled tre-
prostinil doses of 54, 72, 78, 84, and 90 lg were 0.812
(58.1 %), 0.661 (67.3 %), 1.206 (44.3 %), 1.182 (20.2 %),
and 1.579 (51.7 %) ngh/mL, respectively. Treprostinil
pharmacokinetics were dose proportional for AUC?, AUC
from time zero to time t (AUCt), and Cmax (mean range
790–1708 pg/mL). Adverse events of chest pain, chest
discomfort, dyspnea, headache, dizziness, tremor, nausea,
and vomiting in the 90 lg cohort were determined to be
intolerable, and thus the MTD for a single dose of inhaled
treprostinil in healthy volunteers was determined to be
84 lg.
2.2.3 Pharmacokinetics in PAH Patients
A substudy of a phase IV safety study assessed the phar-
macokinetics of inhaled treprostinil following long-term
administration in 17 patients with PAH receiving inhaled
treprostinil for C30 days and on a stable dose for C3 days
prior to pharmacokinetic collection [18]. Across all patients
and doses, the time to Cmax (tmax) ranged from 5 to 30 min.
The geometric mean Cmax for the cohort of 11 PAH
patients receiving the recommended maintenance dose of
54 lg (9 breaths) four times daily for C3 days was
1015.3 pg/mL (CV% = 118 %). At the same dose, the
geometric AUCt was 993.6 hpg/mL (CV% = 151 %)
(Fig. 2). The observed Cmax appears to be consistent with
those previously observed in healthy volunteers receiving
inhaled treprostinil, while AUC? (1023.2 hpg/mL) is
26 % higher in PAH patients than healthy volunteers
Fig. 1 Mean plasma concentration of treprostinil following intra-
venous and subcutaneous infusion: a linear plot and b log-linear plot
[14]. IV intravenous, SC subcutaneous
Fig. 2 Mean (±standard deviation) plasma treprostinil concentration
vs. time following administration of 54 lg of inhaled treprostinil
(n = 11) [18]
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[17, 18]. This effect was not limited to the inhaled for-
mulation and was more pronounced in a systemically
administered treprostinil formulation. PAH patients who
were taking oral treprostinil 2 mg twice daily experienced
approximately 50 % higher Cmax and AUC values than
equivalently dosed healthy volunteers [19, 20].
Additionally, studies were conducted by independent
academic investigators to explore the safety and efficacy of
inhaled treprostinil administered by inhalation at varying
doses and durations [21, 22]. The pharmacokinetic studies
demonstrated that the plasma Cmax of treprostinil was
achieved 10–45 min after inhalation and confirmed dose-
dependent plasma concentrations.
2.3 Orenitram (Treprostinil Diolamine) Extended-
Release Tablets Dosing Overview
Oral treprostinil is an extended-release tablet that utilizes
osmotic release technology. Oral treprostinil has been
studied as both a twice daily and three times daily regi-
men. Oral treprostinil is to be administered to patients at a
recommended starting dose of 0.25 mg twice daily or
0.125 mg three times daily with food [11]. A three times
daily dosing strategy may lower the peak to trough ratio
and allow for a more rapid titration by minimizing
adverse events [23]. The determination of dosing fre-
quency is based on physician discretion. Dose titrations
are recommended to occur in increments of 0.25–0.5 mg
twice daily or 0.125 mg three times daily every 3–4 days,
as tolerated.
The maximum dose of oral treprostinil is dependent on
patient tolerability. The maximum doses studied were
12 mg twice daily in a phase III, 12-week, placebo-con-
trolled study and as high as 27.5 mg three times daily in an
open-label, long-term extension study [5, 24]. The mean
dose in a controlled clinical trial at week 12 was 3.4 mg
twice daily, and the open-label extension study reported
mean doses of 3.1, 3.6, and 4.1 mg twice daily at 6, 12, and
24 months, respectively. Table 3 presents the AUC and
Cmax for varying doses of oral, parenteral, and inhaled
treprostinil for comparison.
2.3.1 Bioavailability and Food Effect
The bioavailability of oral treprostinil 1 mg was compared
with a dose of IV treprostinil 0.2 mg over 4 h
(7.6–14.7 ng/kg/min with a mean of 11.4 ng/kg/min).
Based on the ratios of geometric means for AUC?, the
absolute bioavailability of oral treprostinil was 17 % (90 %
CI 16–19). In this study, oral treprostinil was administered
twice daily with a well-balanced 500 calorie meal based on
the results of food effect studies.
Oral treprostinil administered to healthy volunteers
immediately following a US Food and Drug Administra-
tion (FDA)-designated high-fat, high-calorie meal (con-
taining approximately 800–1000 calories and
approximately 50 % fat) resulted in a 49 % increase in
AUC? and 13 % increase in Cmax compared with fasting
conditions [11]. The tmax value was delayed from 3.5 h in
the fasted state to 6 h following a high-fat, high-calorie
meal, with sustained plasma treprostinil concentrations
observed over 12 h. Additionally, in a study of volunteers
who were randomized to receive 1 mg of oral treprostinil
immediately following four meal types containing varying
calories and fat content, a decrease in treprostinil Cmax and
AUC (5–15 %) was observed with decreasing caloric
intake from 500 to 250 calories or increasing fat content
from 30 to 50 % prior to administration [25]. Overall, these
data indicate that oral treprostinil should be administered
with food but with no specific caloric requirement.
2.3.2 Drug–Drug Interactions:
The majority of drug–drug interaction studies have been
conducted with oral treprostinil, with the data extrapolated
to apply to the IV, SC, and inhaled formulations as
appropriate. Several phase I studies were conducted in
healthy volunteers to evaluate the potential for drug–drug
Table 3 Comparison of total daily dose and pharmacokinetics in pulmonary arterial hypertension patients for various formulations and routes of
administration of treprostinil
Product IV or SC treprostinil Inhaled treprostinil Oral treprostinil
Dose 10 ng/kg/min 54 lg qid 2 mg bid 6 mg bid 7.5 mg tid
AUC24 (ngh/mL) 40.7a 4.1 [18]b 32.0 [19]b 71.0 [19]b 113.2c
Cmax or Css (ng/mL) 1.7
a 1.0 [18] 3.0 [19] 5.3 [19] 11.2c
AUC area under the plasma concentration–time curve, AUC24 AUC from time zero to 24 h, bid twice daily, Cmax maximum concentration, Css
steady-stage concentration, IV intravenous, qid four times daily, SC subcutaneous, tid three times daily
a Estimated from the formula derived by McSwain et al. [16]
b Estimate of total daily AUC
c Estimated from data obtained from White et al. [37]
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interactions with oral treprostinil [26–29]. Based on in vitro
cytochrome P450 (CYP) experiments evaluating the inhi-
bitory and induction potential of treprostinil, it is expected
that treprostinil would have little potential to cause inter-
actions with drugs metabolized by CYP isozymes. Any
drugs that inhibit, induce, or are metabolized by CYP2C8,
and to a lesser extent CYP2C9, may have the potential to
affect the concentrations of treprostinil in the systemic
circulation. Two studies were conducted with prototypical
inducer (rifampin [rifampicin]) and inhibitors (gemfibrozil
and fluconazole) of the CYP2C8 system to determine the
effects of these drugs on the pharmacokinetics of oral
treprostinil. Rifampin reduced treprostinil concentrations
by 30 % and gemfibrozil increased treprostinil concentra-
tions twofold. In the presence of gemfibrozil or other strong
CYP2C8 inhibitors, the starting dose of oral treprostinil
should be reduced to 0.125 mg twice daily and may be
titrated by 0.125 mg twice daily as tolerated. Fluconazole,
a CYP2C9 inhibitor was selected to evaluate the effect of
concomitant use with treprostinil; no significant changes
were noted in the presence of fluconazole.
Concomitant PAH therapies evaluated for drug–drug
interaction potential include bosentan, an ERA, and silde-
nafil, a PDE-5 inhibitor. There were no clinically signifi-
cant or evident treatment-emergent changes or adverse
trends in vital signs or laboratory parameters following
administration of oral treprostinil in combination with
bosentan or sildenafil. Neither bosentan nor sildenafil affect
the pharmacokinetics of treprostinil.
The effect of esomeprazole, a proton pump inhibitor, on
treprostinil pharmacokinetics was also evaluated and no
effect was found. Therefore, no dosing adjustments are
recommended for concomitant use of gastric acid sup-
pressive agents and oral treprostinil. Figure 3 displays the
CIs obtained from all drug interaction studies conducted
with treprostinil diolamine.
In addition, drug interaction studies were conducted
with SC treprostinil sodium co-administered with warfarin
(25 mg/day) in healthy volunteers and acetaminophen in
healthy volunteers. There was no clinically significant
effect of treprostinil on the pharmacokinetics or pharma-
codynamics of warfarin. Additionally, acetaminophen did
not affect the pharmacokinetics of treprostinil [30, 31].
Other important interactions to consider with all tre-
prostinil formulations include concomitant use of antihy-
pertensive agents, diuretics, other vasodilators, and
anticoagulants. When treprostinil is used in combination
with antihypertensive agents, diuretics, or vasodilators,
patients may have an increased risk of symptomatic
hypotension, and the antiplatelet effects of treprostinil may
increase the risk of bleeding when used with anticoagulants
[9–11].
2.3.3 Special Populations
Studies have been conducted in subjects with hepatic and
renal impairment [32, 33]. Relative to healthy volunteers,
mean oral clearance (CL/F) values in subjects with Child-
Pugh class A, B, and C decreased by approximately 57, 76,
and 89 %, respectively [32]. The decrease in CL/F as a
function of hepatic impairment severity resulted in an
increase in exposure levels of treprostinil. Relative to
healthy subjects, mean AUC? values in subjects with mild,
moderate, and severe hepatic impairment increased by
factors of 2.2, 4.9, and 7.6, respectively. Mean Cmax values
in subjects with mild, moderate, and severe hepatic
impairment also increased by factors of 1.6, 4.0, and 4.8,
respectively. As a result of these data, dose adjustments are
suggested for patients with Child-Pugh class A hepatic
dysfunction; however, oral treprostinil should be avoided
in Child-Pugh class B and is contraindicated in class C
patients [11]. The parenteral and inhaled treprostinil for-
mulations bypass first-pass metabolism; therefore, the
effect of hepatic impairment on pharmacokinetics is
reduced.
In the renal impairment study, results demonstrated that
end-stage renal disease (ESRD) did not substantially alter
Fig. 3 Impact of co-administered drugs on the systemic exposure of
oral treprostinil 1 mg compared with oral treprostinil administered
alone [28]. AUC? area under the plasma concentration–time curve
from time zero to infinity, bid twice daily, CI confidence interval,
Cmax maximum concentration, PK pharmacokinetics, qid four times
daily, tid three times daily
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the pharmacokinetics of treprostinil following oral tre-
prostinil administration. Mean plasma exposure to tre-
prostinil in ESRD subjects post-dialysis was approximately
23 % lower than in healthy subjects with normal renal
function. Hemodialysis was not found to contribute sig-
nificantly to the elimination of treprostinil from the sys-
temic circulation; treprostinil pharmacokinetics in ESRD
subjects were largely comparable when oral treprostinil
was administered either 4 h prior to or after dialysis [33].
2.3.4 Long-Term Dosing in PAH Patients
A study of 70 PAH patients evaluated the pharmacokinetic
profile of oral treprostinil after long-term treatment for a
minimum of 4 weeks at doses ranging from 0.5 to 16 mg
twice daily, with 90 % of the patients receiving a dose
of B7 mg twice daily [23]. The mean treprostinil AUC,
Cmax, and minimum concentration (Cmin) increased from
5.24 to 204.09 ngh/mL, 1.38 to 33.59 ng/mL, and 0.05 to
3.68 ng/mL between the 0.5 and 16 mg twice daily dose
levels, respectively. Results of the power analysis suggest
that AUC and Cmax increased in a dose-linear manner
between 0.5 and 15 mg (slope estimates = 0.84 and 0.71,
respectively). In addition, the treprostinil pharmacokinetic
profile appeared to be consistent regardless of patient age,
weight, sex, race, ethnicity, background therapy, or PAH
etiology (including in a cohort of nine patients with con-
nective tissue disease who classically have impaired gut
motility).
2.3.5 Three Times Daily Dosing
A study evaluated the pharmacokinetic profile of oral tre-
prostinil following administration of a dosing regimen of
0.5 mg three times daily for 7 days in healthy volunteers.
On Day 7, mean steady-state plasma treprostinil concen-
trations were maintained above 200 pg/mL for approxi-
mately 20 h over a 24-h interval. Statistical analyses
showed no significant differences in Cmax between Day 7
and Day 1, and no significant differences in the AUC from
time zero to 6 h (AUC6) between Day 7 and Day 1, with
the 90 % CI of the mean Cmax and AUC ratios falling
within the 0.80–1.25 range, indicating equivalence.
Box plots and statistical analysis showed the mean total
exposure (AUC from time zero to 24 h [AUC24]) on Day 7
(after three doses) was not significantly different from three
times the exposure after a single dose on Day 1
(3 9 AUC?), with the 90 % CI of the mean parameter
ratios falling within the 0.80–1.25 range. This study pro-
vides support for a three times daily dosing strategy, which
is currently being evaluated in all ongoing clinical trials
with oral treprostinil. A cohort of 13 PAH patients were
enrolled in an open-label study comparing the
pharmacokinetics and tolerability of twice-daily versus
three times daily dosing. Dosing oral treprostinil using a
three times daily regimen resulted in higher total daily
doses and AUCs while maintaining consistency in the Cmax
and increasing the Cmin approximately twofold compared
with twice-daily dosing. Adverse events were assessed
using the Standardized Subject Impression of Change, with
a net improvement observed in 12 of 13 patients with three
times daily dosing. Overall, three times daily dosing
resulted in a reduction in the peak to trough ratio of
approximately twofold [23, 34]. These data suggest that
three times daily dosing may be an alternative to twice-
daily dosing to improve tolerability.
2.3.6 Oral Treprostinil as a Replacement for Parenteral
Therapy
At physiological pH, treprostinil sodium (SC, IV, and
inhaled formulations) and treprostinil diolamine (oral
tablets) dissociate from their respective salt counterion,
resulting in ionized treprostinil that can circulate freely in
the plasma. Oral treprostinil dose equivalence can be
estimated with the following equation:
Orenitramr total daily dose ðmgÞ
¼ 0:0072 Remodulinr dose ðng=kg=minÞ
 weight ðkgÞ:
Additionally, if there is a treatment interruption with
oral therapy, SC or IV treprostinil could temporarily be




r total daily dose ðmgÞ
Weight ðkgÞ :
Preliminary data from a study evaluating the safety,
tolerability, pharmacokinetics, and logistics of
transitioning clinically stable PAH patients from
parenteral (25–111 ng/kg/min) to oral treprostinil
indicates that the transition is feasible in the majority of
subjects. Figure 4 compares the mean concentration of
parenteral treprostinil with that of oral treprostinil
administered twice daily and three times daily [35].
3 Clinical Impact and Estimates
of Pharmacokinetic Equivalents
The goal of treprostinil dosing in PAH is to establish an
optimal dose at which symptoms are improved, while
minimizing excessive pharmacologic effects associated
with the prostacyclin class of medications (e.g., headache,
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nausea, diarrhea, flushing, jaw pain, vomiting). Experience
with IV and SC treprostinil indicates that patients achieve a
wide range of doses following long-term exposure. While
many factors contribute to the dosing paradigm for each
patient, pharmacokinetic data in healthy volunteers and
patients with PAH indicate that the administration of IV
and SC route are bioequivalent, linear up to 125 ng/kg/min,
have diurnal variation of 20–30 %, and have an elimination
half-life of 4 h [15].
In comparison, inhaled treprostinil is approved for a
target dose of 54 lg four times daily, although data indi-
cate some patients have tolerated doses as high as 72 lg
four times daily [6]. Importantly, the effect of inhaled
treprostinil may not be driven entirely by systemic plasma
concentrations but rather due to the local delivery of tre-
prostinil to the lungs [36]. Pharmacokinetic data demon-
strate dose linearity up to 84 lg, absolute bioavailability of
approximately 65–70 %, and a tmax of 10 min.
Pharmacokinetic studies with oral treprostinil have
addressed bioavailability, food effect, pharmacokinetic
linearity in volunteers and PAH patients, drug interactions,
and use in special populations. The major conclusions from
oral treprostinil pharmacokinetic studies indicate that the
bioavailability (17 %) is affected by food, is linear up to
16 mg twice daily in PAH patients, drug interactions are
present with CYP2C8 inhibitors and inducers, and dose
adjustments are required in patients with hepatic
dysfunction but not patients with renal dysfunction,
including ESRD. Most oral treprostinil studies were con-
ducted with twice-daily dosing, but three times daily dos-
ing has also been evaluated. Three times daily dosing
demonstrated higher systemic exposure than twice-daily
dosing, with a reduction in the plasma treprostinil peak to
trough ratios throughout the day. Less variation in drug
concentrations may reduce the occurrence or severity of
adverse events and therefore improve the rate of titration
[23].
In summary, each route of administration for treprostinil
has unique pharmacokinetic characteristics. Importantly,
regardless of route of administration, the pharmacologi-
cally active agent measured in the plasma is treprostinil
and a direct comparison of systemic exposure can be
obtained (Table 3). The target maintenance dose of inhaled
treprostinil (54 lg four times daily) would deliver the same
systemic exposure as an infused treprostinil dose of 1 ng/
kg/min. When this same comparison is performed with
parenteral and oral treprostinil, the following evaluation
can be made: 1 mg three times daily of oral treprostinil is
approximately equivalent to 5 ng/kg/min of parenteral
treprostinil. Notably, this only holds true for patients who
weigh approximately 70 kg and have no other confounding
factors (i.e., liver dysfunction or receiving a CYP2C8
modifier). For patients who weigh less than or greater than
70 kg, estimation at an equivalent dose should be made
using the equations presented in Sect. 2.3.6.
When deciding between formulations, clinicians should
individualize therapy selection based on the patient’s
clinical status, health literacy, quality of life, co-morbidi-
ties, and any route-specific considerations. Table 1 high-
lights many of the risks and benefits clinicians may
consider when choosing between formulations.
4 Conclusion
In this article we have reviewed and compared pharma-
cokinetic data from studies performed in healthy volunteers
and patients with PAH for three different formulations and
four different routes of administration of treprostinil:
Remodulin (treprostinil sodium, IV and SC administra-
tion), Tyvaso (treprostinil sodium, inhaled administra-
tion), and Orenitram (treprostinil diolamine, oral
administration). Careful consideration of these pharma-
cokinetic data can aid the clinician in making treatment
decisions to select an appropriate route of administration,
as well as to transition between formulations.
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Fig. 4 Mean ± standard error of the mean treprostinil concentration
vs. time plots by treatment regimen (semi-log). Tyvaso has been
omitted from this figure as its systemic effects are not comparable
with parenteral Remodulin or oral treprostinil (Data on file). Mean
dose ± standard deviation of Remodulin (n = 32): 58.2 ± 19.2 ng/
kg/min; total daily mean dose ± standard deviation of oral trepros-
tinil twice daily (n = 6): 27 ± 12.3 mg; total daily mean dose ± s-
tandard deviation of oral treprostinil three times daily (n = 26):
37.9 ± 13.8 mg. bid twice daily, tid three times daily. Data from a
study sponsored by United Therapeutics Corp. The PK report from
this study was dated Feb 2015
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